Disclaimer

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

Please note that you are now entering a website directly or indirectly maintained by a third party (the "External Site") and that you do so at your own risk.

By clicking “Accept” you acknowledge and agree that neither ITGR nor third party provider Virtua Research, Inc. (“Virtua) is responsible, or accepts or assumes any responsibility or liability whatsoever for, the content, the data or the technical operation of the Linked Site. Further, by entering the External Site, you also acknowledge and agree that you completely and irrevocably waive any and all rights and claims against ITGR and Virtua and further acknowledge and agree that in no event shall ITGR or Virtua, its officers, employees, directors and agents be liable for any (i) indirect, consequential, incidental, special, compensatory or punitive damages, (ii) damages for loss of income, loss of business profits, business interruption, loss of data or business information, loss of or damage to property, (iii) claims of third parties, or (iv) other pecuniary loss, arising out of or related to this disclaimer or the External Site

By entering the External Site, you further acknowledge and agree that the disclaimer of warranties and limitations of liability set out in this disclaimer shall apply regardless of the causes, circumstances or form of action giving rise to the loss, damage, claim or liability, even if such loss, damage, claim or liability is based upon breach of contract (including, without limitation, a claim of fundamental breach or breach of a fundamental term), tort (including, without limitation, negligence), strict liability or any other legal or equitable theory, and even if ITGR and Virtua are advised of the possibility of the loss, damage, claim or liability. The waiver and release specifically includes, without limitation, any and all rights and claims pertaining to the processing of personal data, including but not limited to any rights under any applicable data protection statute(s).

If in any jurisdiction, any part of this disclaimer is held to be unenforceable by a court of competent jurisdiction, such part of this disclaimer shall be restricted or eliminated to the minimum extent and the remaining disclaimer shall otherwise remain in full force and effect.

Please note the information presented is deemed representative at the time of its original release. Changes in historical information may occur due to adjustments in accounting and reporting standards & procedures.

Non-GAAP Information

In addition to disclosing results determined in accordance with GAAP, ITGR may also disclose certain non-GAAP and pro forma non-GAAP results of operations, including certain ratios, operational and miscellaneous data, as well as net income, diluted earnings per share, operating expenses, and operating income that make certain adjustments or exclude certain charges and gains that are outlined in the schedules included in this website. Management believes that this non-GAAP and pro forma non-GAAP information provides investors with additional information to assess ITGR operating performance by making certain adjustments or excluding costs or gains and assists investors in comparing our operating performance to prior periods. Management uses this non-GAAP and pro forma non-GAAP information, along with GAAP information, in evaluating its historical operating performance. ITGR and Virtua also take no responsibility for third party pricing data provided for informational purposes and certain ratio results formulated from the provided third party pricing data.

The non-GAAP information is not prepared in accordance with GAAP and may not be comparable to non-GAAP information used by other companies. The non-GAAP information should not be viewed as a substitute for, or superior to, other data prepared in accordance with GAAP.

Integer Holdings Corporation Reports Results for Fourth Quarter and Full Year 2020

February 18 2021

~ Strong 4Q sequential sales and profit increase ~
~ 4Q sales at the high end of guidance, profit above guidance ~
~ Strong cash management … reduced net total debt by $123 million in 2020 ~

PLANO, Texas, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three and twelve months ended December 31, 2020. Unless otherwise stated, all results and comparisons are from continuing operations.

Executing strategy through the COVID-19 pandemic

  • Throughout the pandemic, Integer associates continue to deliver critical products that customers and patients rely on every day.
  • Integer’s Manufacturing Excellence strategic imperative delivered strong operational results in 2020, delivering productivity and continued improvements in safety, quality and on-time delivery.
  • Integer continues to invest in its product line and operational strategy to create long-term value, including manufacturing capabilities, R&D resources and talent additions to execute the strategic imperatives.

Fourth Quarter 2020 Financial Results (compared to fourth quarter 2019, except as noted)

  • Integer delivered fourth quarter sales at the high end of guidance and profit above guidance.
  • Strong sequential improvement versus the third quarter including margin expansion on sales recovery and continued operating efficiencies.
  • Sales declined 17% to $269 million.
  • GAAP net income grew $4 million to $15 million, an increase of 40%. Adjusted net income declined $18 million to $23 million, a decrease of 43%.
  • Adjusted EBITDA declined $24 million to $49 million, a decrease of 33%.
  • GAAP diluted EPS grew $0.14 per share to $0.47 per share, an increase of 42%. Adjusted EPS declined $0.54 per share to $0.71 per share, a decrease of 43%.
  • Net total debt decreased $59 million from the end of the third quarter 2020 to $689 million.

Full Year 2020 Financial Results (compared to full year 2019)

  • Sales declined 15% to $1.073 billion.
  • GAAP net income declined $14 million to $77 million, a decrease of 15%. Adjusted net income declined $63 million to $92 million, a decrease of 41%.
  • GAAP diluted EPS declined $0.43 per share to $2.33 per share, a decrease of 16%. Adjusted EPS declined $1.91 per share to $2.77 per share, a decrease of 41%.
  • Adjusted EBITDA declined $94 million to $190 million, a decrease of 33%.
  • Generated $181 million of cash flow from operating activities.
  • Reduced net total debt by $123 million.

“Our fourth quarter results reflect the beginning of the recovery from the pandemic as both sales and profit improved significantly from the third quarter,” said Joseph Dziedzic, Integer’s president and CEO. “Integer’s dedicated associates continued to deliver for our customers and their patients while executing our strategy to achieve excellence in everything we do. Our strong operational performance and continued strong cash generation last year enabled Integer to increase investments in our strategy versus 2019. During 2020, Integer improved our manufacturing processes, enhanced our customer relationships, built and added leadership capability and strengthened our culture, positioning 2021 to be a return to profitable growth on our Journey to Excellence.”

Discussion of Product Line Fourth Quarter and Full Year Sales

  • Cardio & Vascular sales declined 14% in the fourth quarter and full year sales declined 7%. Sales were negatively impacted by the COVID-19 pandemic and a blend of our customers’ responses across nearly all C&V markets.
  • Cardiac & Neuromodulation sales declined 21% in the fourth quarter and full year sales declined 24%. CRM and Neuromodulation declined due to the COVID-19 pandemic impact and a blend of our customers’ responses. Additionally, the fourth quarter 2019 Nuvectra bankruptcy created a $17 million headwind for the full year.
  • Advanced Surgical, Orthopedics & Portable Medical includes sales to the acquirer of our AS&O product line, Viant, under supply agreements associated with the divestiture. Fourth quarter sales declined 12% and full year sales decreased 8%, driven by the COVID-19 pandemic impact and a blend of our customers’ responses.
  • Electrochem sales declined 41% in the fourth quarter and full year sales declined 39% driven by a severe decline in the energy market and demand fall-out from the COVID-19 pandemic.

2021 Outlook

Our full year 2021 financial outlook reflects an expected recovery of the industry with year-over-year sales growth projected to be 8% to 12%. Integer’s first quarter sales are projected to be sequentially better than the fourth quarter of 2020 and we believe the second quarter should be similar or slightly better than the first quarter. We expect the improvement in the second half of 2021 to be determined by the pace of COVID-19 recovery.

We expect our operating income to reflect the increase in sales and the continued execution of our manufacturing excellence strategic imperative. We project to generate $90 to $110 of free cash flow, with an equivalent amount of net total debt reduction.

2021 Outlook (a)
(dollars in millions, except per share amounts)

First Quarter 2021

    GAAP   Non-GAAP (b)
    As Reported   Change   Adjusted   Change
Sales   $280 to $290   (15)% to (12)%   $280 to $290   (15)% to (12)%
Operating income   $29 to $34   (34)% to (23)%   $42 to $47   (29)% to (20)%

Full Year 2021

    GAAP   Non-GAAP (b)
    As Reported   Change   Adjusted   Change
Sales   $1,160 to $1,200   8% to 12%   $1,160 to $1,200   8% to 12%
Operating income   $116 to $136   (4)% to 13%   $170 to $190   18% to 32%
EBITDA   N/A   N/A   $230 to $250   21% to 32%
Net income   $74 to $91   (4)% to 18%   $113 to $130   23% to 41%
Earnings per Diluted Share   $2.24 to $2.74   (4)% to 17%   $3.40 to $3.90   23% to 41%

 

(a) Except as described below, further reconciliations by line item to the closest corresponding GAAP financial measure for Adjusted operating income, Adjusted EBITDA, Adjusted net income, and Adjusted Earnings per Share (“EPS”), all from continuing operations, included in our “2021 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.
(b) Adjusted operating income for 2021 is expected to consist of GAAP operating income, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions and severance, totaling approximately $54 million ($13 million for first quarter), pre-tax. Adjusted net income and Adjusted EPS for 2021 are expected to consist of GAAP net income and diluted EPS, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions, severance, gains and losses on equity investments and loss on extinguishment of debt totaling approximately $49 million, pre-tax. The after-tax impact of these items is estimated to be approximately $39 million, or approximately $1.16 per diluted share.

Adjusted EBITDA is expected to consist of Adjusted net income, excluding items such as depreciation, interest, stock-based compensation and taxes totaling approximately $116 million to $120 million.

Supplemental Financial Information

  2021
Outlook
  2020
Actual
   
Capital Expenditures, Net $50 - $60   $47    
Depreciation and Amortization $80 - $90   $79    
Stock-Based Compensation $17 - $19   $9    
Other Operating Expense $8 - $12   $8    
Adjusted Effective Tax Rate 15.5% - 17.5%   12.2%    
Cash Tax Payments $20 - $27   $18    
           

Summary of Financial and Product Line Results from Continuing Operations

(dollars in thousands, except per share data)

  Three Months Ended
GAAP December 31,
2020
  December 31,
2019
  Change   Organic Change (a)
Medical Sales              
Cardio & Vascular $ 137,063     $ 158,504     (13.5 ) %   (14.3 ) %
Cardiac & Neuromodulation 93,838     119,262     (21.3 ) %   (21.3 ) %
Advanced Surgical, Orthopedics & Portable Medical 29,747     33,885     (12.2 ) %   (12.2 ) %
Total Medical Sales 260,648     311,651     (16.4 ) %   (16.7 ) %
Non-Medical Sales 8,311     13,986     (40.6 ) %   (40.6 ) %
Total Sales $ 268,959     $ 325,637     (17.4 ) %   (17.8 ) %
               
Income from continuing operations $ 15,427     $ 11,044     39.7   %    
Diluted EPS from continuing operations $ 0.47     $ 0.33     42.4   %    
               
  Year Ended
GAAP December 31,
2020
  December 31,
2019
  Change   Organic Change (a)
Medical Sales              
Cardio & Vascular $ 569,948     $ 610,056     (6.6 ) %   (7.7 ) %
Cardiac & Neuromodulation 346,242     457,194     (24.3 ) %   (24.3 ) %
Advanced Surgical, Orthopedics & Portable Medical 121,788     132,429     (8.0 ) %   (8.0 ) %
Total Medical Sales 1,037,978     1,199,679     (13.5 ) %   (14.0 ) %
Non-Medical Sales 35,464     58,415     (39.3 ) %   (39.3 ) %
Total Sales $ 1,073,442     $ 1,258,094     (14.7 ) %   (15.2 ) %
               
Income from continuing operations $ 77,258     $ 91,218     (15.3 ) %    
Diluted EPS from continuing operations $ 2.33     $ 2.76     (15.6 ) %    

 

(a) Organic sales change is a Non-GAAP measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table C at the end of this release for a reconciliation of these amounts.
   

 

  Three Months Ended
Non-GAAP (a) December 31,
2020
  December 31,
2019
  Change   Organic Change (b)
Adjusted EBITDA $ 49,236     $ 73,273     (32.8 ) %   (30.6 ) %
Adjusted net income $ 23,424     $ 41,421     (43.4 ) %   (40.4 ) %
Adjusted EPS $ 0.71     $ 1.25     (43.2 ) %   (40.5 ) %
               
  Year Ended
Non-GAAP (a) December 31,
2020
  December 31,
2019
  Change   Organic Change (b)
Adjusted EBITDA $ 189,616     $ 283,770     (33.2 ) %   (32.9 ) %
Adjusted net income $ 91,849     $ 154,468     (40.5 ) %   (39.8 ) %
Adjusted EPS $ 2.77     $ 4.68     (40.8 ) %   (40.0 ) %

 

(a) Refer to Tables A and B at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.
(b) Organic change rates for Adjusted EBITDA from continuing operations, Adjusted net income, and Adjusted EPS are Non-GAAP measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.
   

Conference Call Information
The Company will host a conference call on Thursday, February 18, 2021, at 9:00 a.m. EDT / 8:00 a.m. CDT to discuss these results. The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (833) 714-0898 (U.S.) or (778) 560-2691 (outside U.S.) and the conference ID is 1898248. The call will be archived on the Company’s website. An earnings call slide presentation containing supplemental information about the Company’s results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.

From time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.

About Integer ®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

Contact Information
Tony Borowicz
SVP, Strategy, Business Development & Investor Relations
716.759.5809
tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information

In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted EBITDA margin, adjusted operating income, adjusted operating income margin, and organic change rates, all from continuing operations. Adjusted net income and adjusted EPS consist of GAAP amounts from continuing operations adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) (gain) loss on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding. EBITDA is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure. Adjusted EBITDA consists of EBITDA plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi).

Adjusted operating income consists of operating income from continuing operations adjusted for the same items listed above except for items (viii), (ix), (x) and (xi). Adjusted operating income margin is adjusted operating income as a percentage of sales.

Adjusted EBITDA margin is adjusted EBITDA as a percentage of sales. Organic sales change is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired or divested during the period from the current/previous period amounts, respectively.

Organic change rates for adjusted EBITDA, adjusted net income and adjusted EPS exclude the impact of foreign currency exchange gains and losses included in other (income) loss, net, and the contribution of acquisitions. Contribution of acquisitions represents results, based on the growth rate being presented, attributable to acquired entities for the first four full quarters plus any partial period since the entities' acquisition date. After the completion of four full fiscal quarters, results of the acquired entity are treated as organic for current and comparable historical periods.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted operating income, adjusted operating income margin, and organic change rates, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.

Forward-Looking Statements

Some of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: the duration, scope and impact of the COVID-19 pandemic, including government, social, business and other actions taken in response to the pandemic and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our ability to respond to changes in technology; the intense competition we face and our ability to successfully market our products; our ability to develop new products and expand into new geographic and product markets; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability claims; our ability to protect our intellectual property and proprietary rights; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; our ability to integrate acquisitions and operate acquired businesses in accordance with expectations; our dependence upon our senior management team and technical personnel; our ability to realize the benefits from cost savings and consolidation initiatives; interruptions in our manufacturing operations; our ability to comply with environmental regulations; our complex international tax profile; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; market, financial and other risks related to our international operations and sales; global economic factors, including currency exchange rates and interest rates; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

         
         
Condensed Consolidated Statements of Operations - Unaudited        
(in thousands except per share data)              
       
  Three Months Ended   Year Ended
  December 31,
2020
  December 31,
2019
  December 31,
2020
  December 31,
2019
Sales $ 268,959       $ 325,637       $ 1,073,442       $ 1,258,094    
Cost of sales 195,750       249,607       787,735       903,084    
Gross profit 73,209       76,030       285,707       355,010    
Operating expenses:              
Selling, general and administrative (SG&A) 35,037       37,661       109,006       138,695    
Research, development and engineering 10,589       11,809       48,468       46,529    
Other operating expenses (OOE) (10 )     3,912       7,621       12,151    
Total operating expenses 45,616       53,382       165,095       197,375    
Operating income 27,593       22,648       120,612       157,635    
Interest expense 9,218       12,766       38,220       52,545    
(Gain) loss on equity investments, net (1,383 )     (191 )     (5,337 )     475    
Other (income) loss, net 1,755       343       1,522       (578 )  
Income from continuing operations before income taxes 18,003       9,730       86,207       105,193    
Provision (benefit) for income taxes 2,576       (1,314 )     8,949       13,975    
Income from continuing operations $ 15,427       $ 11,044       $ 77,258       $ 91,218    
               
Discontinued operations:              
Income (loss) from discontinued operations before taxes       (20 )           5,296    
Provision for income taxes                   178    
Income (loss) from discontinued operations $       $ (20 )     $       $ 5,118    
               
Net income $ 15,427       $ 11,024       $ 77,258       $ 96,336    
               
Basic earnings per share:              
Income from continuing operations $ 0.47       $ 0.34       $ 2.35       $ 2.80    
Income from discontinued operations $       $       $       $ 0.16    
Basic earnings per share $ 0.47       $ 0.34       $ 2.35       $ 2.95    
               
Diluted earnings per share:              
Income from continuing operations $ 0.47       $ 0.33       $ 2.33       $ 2.76    
Income from discontinued operations $       $       $       $ 0.15    
Diluted earnings per share $ 0.47       $ 0.33       $ 2.33       $ 2.92    
               
Weighted average shares outstanding:              
Basic 32,880       32,688       32,845       32,627    
Diluted 33,129       33,089       33,113       33,037    

 

 
Condensed Consolidated Balance Sheets - Unaudited
(in thousands)
   
  December 31,
2020
  December 31,
2019
ASSETS      
Current assets:      
Cash and cash equivalents $ 49,206     $ 13,535    
Accounts receivable, net 156,207     191,985    
Inventories 149,323     167,256    
Refundable income taxes 2,087        
Contract assets 40,218     24,767    
Prepaid expenses and other current assets 15,896     17,852    
Total current assets 412,937     415,395    
Property, plant and equipment, net 253,964     246,185    
Goodwill 859,442     839,617    
Other intangible assets, net 757,224     775,784    
Deferred income taxes 4,398     4,438    
Operating lease assets 45,153     42,379    
Other long-term assets 38,739     29,295    
Total assets $ 2,371,857     $ 2,353,093    
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities:      
Current portion of long-term debt $ 37,500     $ 37,500    
Accounts payable 51,570     64,975    
Income taxes payable 1,847     3,023    
Current portion of lease liabilities 8,431     7,507    
Accrued expenses and other current liabilities 56,843     66,073    
Total current liabilities 156,191     179,078    
Long-term debt 693,758     777,272    
Deferred income taxes 182,304     187,978    
Operating lease liabilities 37,861     37,114    
Other long-term liabilities 30,688     19,163    
Total liabilities 1,100,802     1,200,605    
Stockholders’ equity:      
Common stock 33     33    
Additional paid-in capital 700,814     701,018    
Treasury stock     (8,809 )  
Retained earnings 517,516     440,258    
Accumulated other comprehensive income 52,692     19,988    
Total stockholders’ equity 1,271,055     1,152,488    
Total liabilities and stockholders’ equity $ 2,371,857     $ 2,353,093    

 

 
Condensed Consolidated Statements of Cash Flows (a) - Unaudited
(in thousands)
  Year Ended
  December 31,
2020
  December 31,
2019
Cash flows from operating activities:      
Net income $ 77,258       $ 96,336    
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 79,324       77,895    
Debt related charges included in interest expense 4,774       7,772    
Stock-based compensation 9,163       9,294    
Non-cash charges related to customer bankruptcy 554       21,695    
Non-cash lease expense 7,810       7,443    
Non-cash (gain) loss on equity investments (5,337 )     475    
Contingent consideration fair value adjustment (2,000 )        
Other non-cash (gains) losses 600       (162 )  
Deferred income taxes (6,966 )     (10,285 )  
Gain on sale of discontinued operations       (4,974 )  
Changes in operating assets and liabilities, net of acquisitions:      
Accounts receivable 38,153       (6,976 )  
Inventories 18,441       3,724    
Prepaid expenses and other assets (864 )     (6,293 )  
Contract assets (15,451 )     (24,767 )  
Accounts payable (9,055 )     1,887    
Accrued expenses and other liabilities (10,721 )     (2,744 )  
Income taxes (4,342 )     (4,962 )  
Net cash provided by operating activities 181,341       165,358    
Cash flows from investing activities:      
Acquisition of property, plant and equipment (46,832 )     (48,198 )  
Purchase of intangible asset (4,607 )        
Proceeds from sale of property, plant and equipment 82       28    
Purchase of equity investments       (417 )  
Proceeds from sale of discontinued operations       4,734    
Acquisitions, net (5,219 )     (15,009 )  
Net cash used in investing activities (56,576 )     (58,862 )  
Cash flows from financing activities:      
Principal payments of long-term debt (87,500 )     (111,500 )  
Proceeds from senior secured revolving line of credit 185,000       34,000    
Payments of senior secured revolving line of credit (185,000 )     (39,000 )  
Proceeds from the exercise of stock options 3,263       3,242    
Payment of debt issuance costs (515 )     (1,385 )  
Tax withholdings related to net share settlements of restricted stock unit awards (3,820 )     (3,283 )  
Principal payments on finance leases (6 )        
Net cash used in financing activities (88,578 )     (117,926 )  
Effect of foreign currency exchange rates on cash and cash equivalents (516 )     (604 )  
Net increase (decrease) in cash and cash equivalents 35,671       (12,034 )  
Cash and cash equivalents, beginning of year 13,535       25,569    
Cash and cash equivalents, end of year $ 49,206       $ 13,535    

 

(a) The Condensed Consolidated Statements of Cash Flows - Unaudited includes cash flows related to discontinued operations.
   

Reconciliations of Non-GAAP Measures from Continuing Operations
Table A: Income from Continuing Operations and Diluted EPS Reconciliations
(dollars in thousands, except per share data)

  Three Months Ended
  December 31, 2020   December 31, 2019
  Pre-Tax   Net of
Tax
  Per
Diluted
Share
  Pre-Tax   Net of
Tax
  Per
Diluted
Share
Income from continuing operations (GAAP) $ 18,003       $ 15,427       $ 0.47       $ 9,730       $ 11,044       $ 0.33    
Adjustments(a):                      
Amortization of intangibles 10,237       8,095       0.24       10,609       8,310       0.25    
Certain legal expenses (SG&A)(b) 139       111             402       318       0.01    
Other operating expenses (OOE)(c) (10 )     235       0.01       3,912       3,020       0.09    
Gain on equity investments, net (1,383 )     (1,093 )     (0.03 )     (191 )     (150 )        
Loss on extinguishment of debt 550       435       0.01       1,280       1,012       0.03    
Customer bankruptcy (excluding OOE)(d) 16       13             23,827       18,823       0.57    
Tax adjustments       201       0.01             (956 )     (0.03 )  
Adjusted net income (Non-GAAP) $ 27,552       $ 23,424       $ 0.71       $ 49,569       $ 41,421       $ 1.25    
                       
Diluted weighted average shares for adjusted EPS     33,129               33,089        
                       
  Year Ended
  December 31, 2020   December 31, 2019
  Pre-Tax   Net of
Tax
  Per
Diluted
Share
  Pre-Tax   Net of
Tax
  Per
Diluted
Share
Income from continuing operations (GAAP) $ 86,207       $ 77,258       $ 2.33       $ 105,193       $ 91,218       $ 2.76    
Adjustments(a):                      
Amortization of intangibles 41,131       32,520       0.98       40,076       31,634       0.96    
Certain legal expenses (gains) (SG&A)(b) (26,811 )     (21,180 )     (0.64 )     2,577       2,036       0.06    
Other operating expenses (OOE)(c) 7,621       6,177       0.19       12,151       9,326       0.28    
(Gain) loss on equity investments, net (5,337 )     (4,216 )     (0.13 )     475       376       0.01    
Loss on extinguishment of debt 550       435       0.01       2,545       2,011       0.06    
Customer bankruptcy (excluding OOE)(d) 1,229       971       0.03       23,827       18,823       0.57    
Tax adjustments       (116 )                 (956 )     (0.03 )  
Adjusted net income (Non-GAAP) $ 104,590       $ 91,849       $ 2.77       $ 186,844       $ 154,468       $ 4.68    
                       
Diluted weighted average shares for adjusted EPS(l)     33,113               33,037        

 

(a) The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.
(b) Represents the net gain of $28.2 million, recorded during the third quarter of 2020 and received in the fourth quarter of 2020, in connection with the resolution of the AVX Corporation patent litigation matter, as well as expenses associated with non-ordinary course legal matters.
(c) Other operating expenses includes acquisition and integration related expenses, facility consolidation, optimization, manufacturing transfer and system integration charges, asset write-down and disposition charges, charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items. Other operating expenses for the fourth quarter of 2020 includes a $1.5 million adjustment to reduce the the fair value of acquisition-related contingent consideration liabilities.
(d) In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). During the fourth quarter of 2019, we recorded pre-tax charges totaling $24.2 million in connection with the Customer Bankruptcy. These expenses were primarily non-cash and included charges associated with certain Nuvectra-related assets, primarily consisting of inventory, accounts receivable, as well as certain non-cancelable inventory commitments. These charges were included in cost of sales ($21.4 million), SG&A expenses ($2.4 million) and Other Operating Expenses ($0.4 million) in our consolidated statement of operations. During 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales in our consolidated statement of operations.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.

Table B: EBITDA and Sales Reconciliations
(in thousands)

  Three Months Ended   Year Ended
  December 31,
2020
  December 31,
2019
  December 31,
2020
  December 31,
2019
Income from continuing operations (GAAP) $ 15,427       $ 11,044       $ 77,258       $ 91,218  
               
Interest expense 9,218       12,766       38,220       52,545  
Provision (benefit) for income taxes 2,576       (1,314 )     8,949       13,975  
Depreciation 10,082       9,889       38,193       37,819  
Amortization of intangibles 10,237       10,609       41,131       40,076  
EBITDA from continuing operations (Non-GAAP) 47,540       42,994       203,751       235,633  
Certain legal expenses (gains) 139       402       (26,811 )     2,577  
Stock-based compensation (excluding OOE) 2,934       2,329       9,163       9,107  
Other operating expenses (OOE) (10 )     3,912       7,621       12,151  
(Gain) loss on equity investments, net (1,383 )     (191 )     (5,337 )     475  
Customer bankruptcy (excluding amounts in OOE) 16       23,827       1,229       23,827  
Adjusted EBITDA (Non-GAAP) $ 49,236       $ 73,273       $ 189,616       $ 283,770  
               
Total sales (GAAP) $ 268,959       $ 325,637       $ 1,073,442       $ 1,258,094  
               
Adjusted EBITDA margin 18.3   %   22.5   %   17.7   %   22.6 %
                             

Table C: Organic Sales from Continuing Operations Change Reconciliation (% Change)

  GAAP
Reported
Growth
  Impact of
Acquisitions
and Foreign
Currency
(a)
  Non-GAAP
Organic
Change
Quarter over Quarter Change (4Q 2020 vs. 4Q 2019)          
Medical Sales          
Cardio & Vascular (13.5)%   (0.8)%   (14.3)%
Cardiac & Neuromodulation (21.3)%     (21.3)%
Advanced Surgical, Orthopedics & Portable Medical (12.2)%     (12.2)%
Total Medical Sales (16.4)%   (0.3)%   (16.7)%
Non-Medical Sales (40.6)%     (40.6)%
Total Sales (17.4)%   (0.4)%   (17.8)%
           
Year over Year Change (2020 vs. 2019)          
Medical Sales          
Cardio & Vascular (6.6)%   (1.1)%   (7.7)%
Cardiac & Neuromodulation (24.3)%     (24.3)%
Advanced Surgical, Orthopedics & Portable Medical (8.0)%     (8.0)%
Total Medical Sales (13.5)%   (0.5)%   (14.0)%
Non-Medical Sales (39.3)%     (39.3)%
Total Sales (14.7)%   (0.5)%   (15.2)%

 

(a) Fourth quarter and full year 2020 and 2019 sales have been adjusted to exclude the contribution of business acquisitions and foreign currency exchange rate fluctuations.
   

Table D: Non-GAAP Organic Change Reconciliation (% Change)

  GAAP
Reported
Growth
(a)
  Impact of
Non-GAAP
Adjustments
(b)
  Impact of
Acquisitions
and Foreign
Currency
(c)
  Non-GAAP
Organic
Change
Quarter over Quarter Change (4Q 2020 vs. 4Q 2019)              
EBITDA from continuing operations 10.6%   (43.4)%   2.2%   (30.6)%
Income from continuing operations 39.7%   (83.1)%   3.0%   (40.4)%
Diluted EPS from continuing operations 42.4%   (85.6)%   2.7%   (40.5)%
               
Year over Year Change (2020 vs. 2019)              
EBITDA from continuing operations (13.5)%   (19.7)%   0.3%   (32.9)%
Income from continuing operations (15.3)%   (25.2)%   0.7%   (39.8)%
Diluted EPS from continuing operations (15.6)%   (25.2)%   0.8%   (40.0)%

 

(a) EBITDA is a non-GAAP financial measure. See Table B for a reconciliation to the most comparable GAAP measure.
(b) Represents the impact to our growth rate from our Non-GAAP adjustments. See Tables A and B for further detail on these items.
(c) Represents the impact to our growth rate due to changes in foreign currency exchange rates realized in income and reported in other (income) loss, net in the consolidated statements of operations, and the adjustment to exclude the contribution of acquisitions when applicable.
   

Table E: Net Total Debt Reconciliation
(in thousands)

  December 31,
2020
  December 31,
2019
Current portion of long-term debt $ 37,500     $ 37,500  
Long-term debt 693,758     777,272  
Total debt 731,258     814,772  
Add: Unamortized discount and debt issuance costs 6,715     10,702  
Total principal amount of debt outstanding 737,973     825,474  
LESS: Cash and cash equivalents 49,206     13,535  
Net Total Debt (Non-GAAP) $ 688,767     $ 811,939  

Primary Logo

Source: Integer Holdings Corporation